Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses Meeting Abstract

  

Authors:	Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; Di Simone, C.; Shaffer, D. R.; Girones Sarrio, R.; Gunnestad Ribe, S.; Wu, J.; Schmidt, E.; Kubiak, P.; Okpara, C. E.; Smith, A. D.; Motzer, R. J.
Abstract Title:	Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
Meeting Title:	ESMO Virtual Congress 2020
Journal Title:	Annals of Oncology
Volume:	31
Issue:	Suppl. 4
Meeting Dates:	2020 Sep 19-21/Oct 16-18
Meeting Location:	Virtual
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2020-09-01
Start Page:	S558
End Page:	S559
Language:	English
ACCESSION:	WOS:000573469100706
DOI:	10.1016/j.annonc.2020.08.782
PROVIDER:	wos
Notes:	Meeting Abstract: 710P -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/172735